Participant flow

Lenalidomide Maintenance Therapy for Multiple Myeloma · Source last updated 2018-02-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity. Lenalidomide: 10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.

   id

   FG000

   title

   Lenalidomide Maintenance Therapy for Multiple Myeloma

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Lenalidomide outside NIH

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Physician Decision

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      No treatment, per protocol

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice